You are here:

News

Published on

Updated:

Sanofi reports issues around safety study into valproate

New prescribing practices for valproate were introduced in December last year, after a safety study suggested there could be risk of harm for babies through paternal exposure pre-conception. Now the drug manufacturer says there are issues with the safety study and that further analysis is necessary.
It is important never to stop taking valproate – or any medication – without consulting your doctor.

LET'S STAY IN TOUCH...

We send monthly e-newsletters to keep you informed with tips for managing epilepsy, the latest news, inspirational stories, fundraising opportunities and further information from Epilepsy Society.

Read our privacy policy

It is always your choice as to whether you want to receive information from us. You may opt-out of our marketing communications by clicking the ‘unsubscribe’ link at the end of our marketing emails or through our unsubscribe number 01494 601 300.